Physician profile
Manish Gupta
NPI 1144262023
$2,782.67
in general payments reported to CMS, 2019-2025
38 companies · $994 in 2025
The $994 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2021: $30.14 · 2022: $142 · 2023: $423 · 2024: $927 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,343.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $435.58 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $295.74 | 2021-2025 | |
| Pfizer INC. | $252.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $187.50 | 2019-2025 | Imfinzi, Enhertu |
| Abbvie INC. | $168.94 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $147.66 | 2019-2023 | Imbruvica, Epkinly |
| Genmab U.S., INC. | $124.99 | 2024 | Epkinly |
| Dendreon Pharmaceuticals LLC | $122.27 | 2019 | |
| Kite Pharma, INC. | $83.55 | 2024-2025 | Yescarta |
| Sirtex Medical INC | $76.25 | 2024 | Sir-Spheres Microspheres |
| Gilead Sciences, INC. | $67.30 | 2021-2025 | Trodelvy |
| Legend Biotech USA INC. | $66.60 | 2025 | Carvykti |
| Array Biopharma INC | $58.15 | 2025 | Mektovi, Braftovi, Tukysa |
| Janssen Biotech, INC. | $57.17 | 2024-2025 | Tecvayli, Talvey, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $49.52 | 2024-2025 | Opdivo |
Show all 37 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.